Articles Related to antibody
GMP-Compliant Production of a Fluorescent Antibody for in vivo Molecular Endoscopy in a Phase I/IIa Clinical Study in Inflammatory Bowel Disease Patients
Therapeutic response to anti-TNF antibody treatment in inflammatory bowel diseases is strongly influenced by transmembrane tumor necrosis factor (mTNF) expression in the intestinal mucosa. Fluorescent anti-TNF antibodies applied for in vivo molecular endoscopy have shown to be able to quantify mucosal mTNF expression in real-time and predict response to subsequent anti-TNF treatment in individual patients with Crohn’s.
Monoclonal Antibodies for the CIGB-552 Antitumor Synthetic Peptide Quantification
The CIGB-552 peptide is a synthetic peptide that exerts cytotoxic effect on tumor cells. Thus, CIGB-552 peptide quantification in patient samples is crucial for assessing the treatment efficacy. Therefore, this study describes the generation and characterization of monoclonal antibodies (mAb) directed against the CIGB-552 peptide to be used in a quantification assay in further pharmacokinetic studies in humans. In this sense, the CIGB.552-H294 mAb specificity was evidenced only against the CIGB-552 peptide and a metabolite of 17 amino acids resulting from the CIGB-552 peptide degradation detected in mouse sera.
Analysis of antibody by Real-Valued Special Functions
Along with the rapid development of genetic engineering technology and antibody engineering technology, the humanized monoclonal antibody has been rapidly developed and gradually replaces the rat sourced monoclonal antibody. In this paper, we establish two new logarithmically completely monotonic functions involving the real-valued special functions according to two preferred interaction geometries, necessary and sufficient conditions are presented for one of them to be logarithmically completely monotonic. As a consequence, a sharp inequality involving the real-valued special functions is deduced to solve the problems of genetically engineered antibody.
Giemsa Staining and Antibody Characterization of Colpodella sp. (Apicomplexa)
Colpodella species are free-living alveolates that possess an apical complex used for attaching to eukaryotic prey protists for ingestion of the cytoplasmic contents of the prey. Colpodella sp. are the closest relatives of the Apicomplexa, a phylum that includes the important human pathogens Plasmodium falciparum, Toxoplasma gondii and Cryptosporidium parvum. In this study, we investigated morphological characteristics of Colpodella (ATCC 50594) in a diprotist culture containing Bodo caudatus as prey in order to identify features differentiating both protists. The level of apical complex protein conservation among free living alveolate relatives of apicomplexans and intracellular apicomplexan pathogens is unknown. Antibodies against proteins of the apical complex in Colpodella sp. are currently unavailable. We performed staining and immunological characterization of Colpodella in a diprotist culture containing B. caudatus to aid routine differentiation of predator and prey in culture. Staining revealed distinguishing morphological features of both protists. The kinetoplast in B.caudatus was identified using Giemsa staining and was used to differentiate B. caudatus from Colpodella sp. trophozoites.
Validation of an Anti-Protective Antigen ELISA for Quantitative IgG Evaluation in B. anthracis Immunized Horses
The potency test for anthrax vaccines has historically involved the challenge of actively or passively immunized laboratory animals with a fully virulent strain of Bacillus anthracis. Lethal challenge studies with the archetypal virulent strains such as B. anthracis Ames strain present considerable difficulties in laboratory management and handling and are too inefficient for the early evaluation of alternative preventative and therapeutic interventions. An ELISA for the evaluation of antibody response to protective antigen (PA) in horses immunized with the Sterne 34F2 strain spore vaccine was developed. The objective of this work was to study the performance of this assay in terms of the guidelines set forth by the International Conference on Harmonics (ICH) and the Center for Biologics Evaluation and Research (CBER) for analytical procedures. We have demonstrated a working range for this assay (73-1581 EU/ml) on the bases of the following parameters: linearity (25 and 1,662 EU/ml, r2 = 0.9988, p < 0.001), accuracy (94.8 - 105.4 %, recovery within the range of 25 and 1,662 EU/ml), precision (≤ 17.6 % CV, repeatability; ≤ 15.7 and ≤ 13.1 % CV, intermediate precision per day and per analyst, respectively), limit of detection (2.25 EU/ml) and limit of quantitation (25 EU/ml). The assay was also demonstrated to be specific for the evaluation of anti-PA IgG antibodies. Based on the assay performance characteristics it was determined that the assay was adequate for use in B. anthracis immunogenicity testing in horses.
Hereditary Spherocytosis and Venous Thrombosis of Atypical Site: A Triple Hematologic Disease?
A 22 year-old male with an unspecified family history of hematologic diseases was admitted complaining of chest pain.
Anti-GnRH Receptor Monoclonal Antibodies, First-In-Class GnRH Analog
A monoclonal antibody (Mab) designated as GHR106 was generated against the extracellular domain (N1-29 synthetic peptide) of human gonadotropin releasing hormone (GnRH) receptor. It is a first-in-class GnRH analog and can serve as a drug candidate for potential applications in the treatment of human cancers and/or fertility regulations.
Phase II Trial of Lower Dose Bevacizumab and Irinotecan in Relapsed High Grade Gliomas
Relapsed high-grade gliomas (HGG) respond poorly to known chemotherapeutic agents with a median survival of 3 to 6 months. Several phase II trials of Bevacizumab for salvage therapy, reported excellent response rates. The optimal dose of Bevacizumab in GBM has not been defined to date. We performed a prospective phase II trial of bevacizumab using 5 mg/kg every 2 weeks.
Study on Efficiency of Protein Extractants Employed for Human Origin Determination of Blood
Human origin determination is an important aspect of blood grouping analysis in forensic science laboratories. In the present study, protein extractants like gel buffer, ammonia and saline employed for origin determination were evaluated and compared qualitatively and quantitatively for their role in the extraction of proteins from dried blood stained materials of human origin at regular time intervals.
Editorial Board Members Related to antibody
Amolak Singh
Professor
Department of Radiology
University of Missouri Health Care
United States
Department of Radiology
University of Missouri Health Care
United States
Azad Kumar Kaushik
Associate Professor
Department of Immunology
University of Guelph
Canada
Department of Immunology
University of Guelph
Canada
Subash Sad
Professor
Department of Biochemistry, Microbiology and Immunology
University of Ottawa
Canada
Department of Biochemistry, Microbiology and Immunology
University of Ottawa
Canada
Matthias Clauss
Associate Professor
Department of Medicine
Indiana University
United States
Department of Medicine
Indiana University
United States
Konstantin N Konstantinov
Professor
Department of Internal Medicine
University of New Mexico
United States
Department of Internal Medicine
University of New Mexico
United States